Opicapona para el tratamiento de la enfermedad de Parkinson: datos de vida real en España.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • López-Ariztegui N
  • Mata-Alvarez Santullano M
  • Tegel I
  • Almeida F
  • Sarasa P
  • Rojo R
  • Rico-Villademoros F
  • Abril-Jaramillo J
  • Bermejo P
  • Borrue C
  • Caballol N
  • Clavero P
  • García-Caldentey J
  • Gómez-Mayordomo V
  • Labandeira C
  • Martí-Andrés G
  • Martínez-Castrillo JC
  • Martinez-Poles J
  • Muñoz T
  • Salom JM
  • Valderrama-Martín C
  • Vinagre-Aragón A

Abstract

Opicapone is a catechol-O-methyl-transferase (iCOMT) inhibitor authorized in Europe in 2016 and indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. The efficacy of opicapone in these patients has been demonstrated in two pivotal randomized clinical trials, BIPARK I and BIPARK II, in which it has demonstrated its superiority versus placebo and non-inferiority versus entacapone. Although they constitute the gold standard for the evaluation of interventions, randomized clinical trials present limitations of external validity due to the use of strict eligibility criteria. Therefore, it is considered necessary to have a more comprehensive evaluation of the efficacy of the drug, complementing the information obtained from randomized clinical trials with that of "real world or real clinical practice" studies. The objective of this review has been to collect and put into perspective the information available on opicapone coming from real clinical practice studies in Spain. The data from Spain with opicapone in 18 series with more than 1,000 patients in total, confirm the safety and efficacy previously reported with this iCOMT. Furthermore, they show that opicapone is especially useful in patients with a less advanced stage of the disease and mild motor fluctuations, which would suggest that the earlier its introduction in the therapeutic scheme for the management of motor fluctuations, the better is the benefit-risk ratio for the drug.

Datos de la publicación

ISSN/ISSNe:
0210-0010, 1576-6578

REVISTA DE NEUROLOGIA  IMR PRESS

Tipo:
Article
Páginas:
1-14
PubMed:
34897643
Factor de Impacto:
0,297 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Catechol-O-methyl-transferase inhibitors; Motor fluctuations; Observational studies; Opicapone; Parkinson's disease; Real-world studies

Campos de Estudio

Cita

Compartir